138 related articles for article (PubMed ID: 37267865)
21. YY1-regulated lncRNA SOCS2-AS1 suppresses HCC cell stemness and progression via miR-454-3p/CPEB1.
Zhong F; Wang Y
Biochem Biophys Res Commun; 2023 Oct; 679():98-109. PubMed ID: 37677983
[TBL] [Abstract][Full Text] [Related]
22. LncRNA RGMB-AS1 is activated by E2F1 and promotes cell proliferation and invasion in papillary thyroid carcinoma.
Zhang Z; Li SY; Zhang LB
Eur Rev Med Pharmacol Sci; 2018 Apr; 22(7):1979-1986. PubMed ID: 29687852
[TBL] [Abstract][Full Text] [Related]
23. LncRNA CCND2-AS1 promotes proliferation, migration, and invasion in papillary thyroid carcinoma.
Xia E; Bhandari A; Shen Y; Zhou X; Sindan N; Xiang J; Guan Y; Yang F; Wang O
Biochem Biophys Res Commun; 2018 Feb; 496(2):628-632. PubMed ID: 29366479
[TBL] [Abstract][Full Text] [Related]
24. lncRNA DUXAP8 inhibits papillary thyroid carcinoma cell apoptosis via sponging the miR‑20b‑5p/SOS1 axis.
Pang R; Yang S
Oncol Rep; 2021 May; 45(5):. PubMed ID: 33760128
[TBL] [Abstract][Full Text] [Related]
25. LncRNA SOCS2-AS1 promotes the progression of glioma via regulating ITGB1 expression.
Wu D; Sun J; Wang H; Ma C
Neurosci Lett; 2021 Nov; 765():136248. PubMed ID: 34536509
[TBL] [Abstract][Full Text] [Related]
26. LncRNA GAS8-AS1 suppresses papillary thyroid carcinoma cell growth through the miR-135b-5p/CCND2 axis.
Chen N; Yin D; Lun B; Guo X
Biosci Rep; 2019 Jan; 39(1):. PubMed ID: 30429236
[TBL] [Abstract][Full Text] [Related]
27. Fasting regulates mitochondrial function through lncRNA PRKCQ-AS1-mediated IGF2BPs in papillary thyroid carcinoma.
Zhang X; Zhong Y; Liu L; Jia C; Cai H; Yang J; Wu B; Lv Z
Cell Death Dis; 2023 Dec; 14(12):827. PubMed ID: 38092752
[TBL] [Abstract][Full Text] [Related]
28. The DLG1-AS1/miR-497/YAP1 axis regulates papillary thyroid cancer progression.
Huang Y; Zhang K; Li Y; Dai Y; Zhao H
Aging (Albany NY); 2020 Nov; 12(22):23326-23336. PubMed ID: 33197895
[TBL] [Abstract][Full Text] [Related]
29. LncRNA DNAJC3-AS1 promotes the biological functions of papillary thyroid carcinoma via regulating the microRNA-27a-3p/CCBE1 axis.
Ni T; Li Y; Guo D; Tan L; Xiao Z; Shi Y
Cell Biol Int; 2023 Mar; 47(3):539-547. PubMed ID: 36583660
[TBL] [Abstract][Full Text] [Related]
30. Kawasaki disease: SOCS2-AS1/miR-324-5p/CUEDC2 axis regulates the progression of human umbilical vein endothelial cells.
Zhao J; Chen D
Pediatr Res; 2022 Aug; 92(2):388-395. PubMed ID: 32688371
[TBL] [Abstract][Full Text] [Related]
31. Long non-coding RNA AGAP2-AS1 promotes proliferation and metastasis in papillary thyroid cancer by miR-628-5p/KLF12 axis.
Xu C; Shao Y; Liu J; Yao X; Quan F; Zhao Q; Zhao R; Kou B; Li H; Han P; Wang X; Bai Y; Zheng Z; Zhang S
J Bioenerg Biomembr; 2021 Apr; 53(2):235-245. PubMed ID: 33604734
[TBL] [Abstract][Full Text] [Related]
32. A novel lncRNA n384546 promotes thyroid papillary cancer progression and metastasis by acting as a competing endogenous RNA of miR-145-5p to regulate AKT3.
Feng J; Zhou Q; Yi H; Ma S; Li D; Xu Y; Wang J; Yin S
Cell Death Dis; 2019 Jun; 10(6):433. PubMed ID: 31160577
[TBL] [Abstract][Full Text] [Related]
33. LncRNA CALML3-AS1 suppresses papillary thyroid cancer progression via sponging miR-20a-5p/RBM38 axis.
Zhang X; Zhang X; Jia Q; Li H; Ma R; Yang G; Yin F; Jiang N; Yin D
BMC Cancer; 2022 Mar; 22(1):344. PubMed ID: 35351042
[TBL] [Abstract][Full Text] [Related]
34. HOXD-AS1 is a predictor of clinical progression and functions as an oncogenic lncRNAs in papillary thyroid cancer.
Xu K; Feng Y
J Cell Biochem; 2019 Apr; 120(4):5326-5332. PubMed ID: 30317670
[TBL] [Abstract][Full Text] [Related]
35. Long non-coding RNA OIP5-AS1 serves as a competing endogenous RNA to modulate X-linked inhibitor of apoptosis protein expression via adsorbing miR-429 in papillary thyroid cancer.
Yu CS; Wang YB; Li Q; Yang EL; Dong BB
J Biol Regul Homeost Agents; 2021; 35(3):909-920. PubMed ID: 34155880
[TBL] [Abstract][Full Text] [Related]
36. LncRNA SOCS2-AS1 inhibits progression and metastasis of colorectal cancer through stabilizing SOCS2 and sponging miR-1264.
Zheng Z; Li X; You H; Zheng X; Ruan X
Aging (Albany NY); 2020 May; 12(11):10517-10526. PubMed ID: 32437330
[TBL] [Abstract][Full Text] [Related]
37. LncRNA
Nian R; Li W; Li X; Zhang J; Li W; Pan F; Cheng J; Jin X
Arch Endocrinol Metab; 2023 Jan; 67(1):55-63. PubMed ID: 35929906
[TBL] [Abstract][Full Text] [Related]
38. LncRNA CASC15 promotes the proliferation of papillary thyroid carcinoma cells by regulating the miR-7151-5p/WNT7A axis.
Bai D; Guo C; Wang A; Pang G; Gao J; Wang C; Zhao D; Yang J; Ren J
Pathol Res Pract; 2021 Sep; 225():153561. PubMed ID: 34325316
[TBL] [Abstract][Full Text] [Related]
39. LncRNA LINC00673 inhibits p53 expression by interacting with EZH2 and DNMT1 in papillary thyroid carcinoma.
Meng XF; Zhao LY; Chu XF
Eur Rev Med Pharmacol Sci; 2019 Mar; 23(5):2075-2083. PubMed ID: 30915752
[TBL] [Abstract][Full Text] [Related]
40. The long-noncoding RNA SOCS2-AS1 suppresses endometrial cancer progression by regulating AURKA degradation.
Jian F; Che X; Zhang J; Liu C; Liu G; Tang Y; Feng W
Cell Death Dis; 2021 Apr; 12(4):351. PubMed ID: 33824269
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
